The company's collaboration agreement with Sanofi could soon pay off.
Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on… Investors...
Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak...
Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep...
Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary...
Takeda ( TSE:4502/NYSE:TAK ) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...